

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732;

(b) complements of the sequences provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732;

(d) sequences that hybridize to a sequence provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732, under moderately stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732;

(f) sequences having at least 90% identity to a sequence of SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732; and

degenerate variants of a sequence provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732.

2. (Canceled)

3. (Withdrawn) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Withdrawn) A host cell transformed or transfected with an expression vector according to claim 3.

5.-6. (Canceled)

7. (Currently Amended) A fusion protein comprising at least one polypeptide according to any one of claims 18-~~22~~24.

8. (Withdrawn) An oligonucleotide that hybridizes to a sequence recited in SEQ ID NOs: 588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723 and 732 under moderately stringent conditions.

9.-13. (Canceled)

14. (Withdrawn) A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 8;
- (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and
- (d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

15. (Withdrawn) A diagnostic kit comprising at least one oligonucleotide according to claim 8.

16.-17. (Canceled)

18. (Currently Amended) An isolated polypeptide comprising ~~an~~the amino acid sequence set forth in SEQ ID NO:586.

19. (Currently Amended) An isolated polypeptide comprising an amino acid sequence with at least 90% identity to ~~an~~the amino acid sequence set forth in SEQ ID NOs:586 ~~or~~ 587, wherein the polypeptide stimulates T cells specific for a polypeptide having ~~an~~the amino acid sequence of SEQ ID NO:586.

20. (Currently Amended) An isolated polypeptide comprising at least 10 contiguous residues of ~~an~~the amino acid sequence set forth in SEQ ID NOs:586 ~~or~~ 587, wherein the polypeptide stimulates T cells specific for a polypeptide having ~~an~~the amino acid sequence of SEQ ID NO:586.

21. (Currently Amended) The polypeptide of claim 20, wherein the polypeptide comprises ~~an~~the amino acid sequence set forth in SEQ ID NO:587.

22. (Previously Presented) The polypeptide of claim 20, wherein the polypeptide comprises amino acid residues 35-50 of SEQ ID NO:586.

23. (New) An isolated polypeptide comprising an amino acid sequence with at least 90% identity to the amino acid sequence set forth in SEQ ID NO:587, wherein the polypeptide stimulates T cells specific for a polypeptide having the amino acid sequence of SEQ ID NO:586.

24. (New) An isolated polypeptide comprising at least 10 contiguous residues of the amino acid sequence set forth in SEQ ID NO:587, wherein the polypeptide stimulates T cells specific for a polypeptide having the amino acid sequence of SEQ ID NO:586.